Pursuant to a preliminary report1 on sodium bismuthate soluble, now called sobisminol, this report presents complete clinical data on excretion. This is important in relation to the use of this bismuth compound in antisyphilitic treatment. The results obtained leave no doubt of a prompt and well sustained absorption of bismuth. Continued daily medication sustains concentrations of bismuth in the blood and tissues comparable to those resulting from intramuscular injections. Effects, in general, indicate that oral administration of sobisminol bids fair to be a practical therapeutic measure.
Twelve complete observations were made on seven different persons, i. e., on four healthy male research workers, two male patients and one female patient. Study of the excretion of bismuth in the urine was made with administration of small and of large single doses of sobisminol, of divided weekly doses and of daily doses for two weeks, with both soluble and insoluble
HANZLIK PJ, LEHMAN AJ, RICHARDSON AP, VAN WINKLE W. CLINICAL EXCRETION OF BISMUTH AFTER ORAL ADMINISTRATION OF SOBISMINOL. Arch Derm Syphilol. 1937;36(4):708–724. doi:10.1001/archderm.1937.01480040025002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: